European Erythropoietin Market Outlook 2022
Erythropoietin drugs are protein therapeutics, which is used to treat various types of anaemia. These drugs play a significant role in treating CKD related anaemia and cancer related anaemia. Since its inception, the erythropoietin drugs market has witnessed various technological advancements, which have resulted in development of more effective and long acting EPO drugs.
Launch of biosimilars in the erythropoietin market has increased its affordability. European region is the largest market for erythropoietin biosimilar, which makes it a major market for over all erythropoietin drugs as well. As per RNCOS report “European Erythropoietin Market Outlook 2022”, the market of Europe was valued at US$ 1.4 Billion in 2015. This report provides a detailed analysis of the current and future market scenario of the European erythropoietin market. The report highlights biosimilar erythropoietin at various stages of clinical development. In addition, the report provides insight about the major drivers and challenges, along with the latest trends and developments impacting the industry growth.
Based on segment, the report sub-divides the market into biologics and biosimilar. Currently, biologics hold major share in the European market. However, biosimilar market is poised to witness the highest growth due to their cost effectiveness. Based on country, the report segments the market into Germany, France, UK, Italy, and Spain. The report provides detailed analysis of each country. Moreover, the report also provides the market for various types of EPO (alpha, beta, and darbepoetin alpha amongst other) for each country. Furthermore, the report covers the prevalence and incidences of CKD and cancer for each country under application segmentation. Additionally, the report also provides the patent analysis and pipeline analysis of erythropoietin market.
The last section of the report discusses about the prominent players in European erythropoietin market. A brief business overview and financial information about each of these players has been provided along with their product portfolios. Overall, the research contains exhaustive information that will help clients in formulating market strategies and assessing opportunity areas in the European erythropoietin market.
Launch of biosimilars in the erythropoietin market has increased its affordability. European region is the largest market for erythropoietin biosimilar, which makes it a major market for over all erythropoietin drugs as well. As per RNCOS report “European Erythropoietin Market Outlook 2022”, the market of Europe was valued at US$ 1.4 Billion in 2015. This report provides a detailed analysis of the current and future market scenario of the European erythropoietin market. The report highlights biosimilar erythropoietin at various stages of clinical development. In addition, the report provides insight about the major drivers and challenges, along with the latest trends and developments impacting the industry growth.
Based on segment, the report sub-divides the market into biologics and biosimilar. Currently, biologics hold major share in the European market. However, biosimilar market is poised to witness the highest growth due to their cost effectiveness. Based on country, the report segments the market into Germany, France, UK, Italy, and Spain. The report provides detailed analysis of each country. Moreover, the report also provides the market for various types of EPO (alpha, beta, and darbepoetin alpha amongst other) for each country. Furthermore, the report covers the prevalence and incidences of CKD and cancer for each country under application segmentation. Additionally, the report also provides the patent analysis and pipeline analysis of erythropoietin market.
The last section of the report discusses about the prominent players in European erythropoietin market. A brief business overview and financial information about each of these players has been provided along with their product portfolios. Overall, the research contains exhaustive information that will help clients in formulating market strategies and assessing opportunity areas in the European erythropoietin market.
1. ANALYST VIEW
2. RESEARCH METHODOLOGY
3. EUROPEAN PROTEIN THERAPEUTICS MARKET
3.1 Protein Therapeutics Market Vs Pharmaceutical Market
3.2 Current and Future Market Analysis for 2022
3.3 Market Segmentation
4. ERYTHROPOIETIN MARKET - INTRODUCTION
5. EUROPEAN ERYTHROPOIETIN MARKET OUTLOOK 2022
5.1 By Segment
5.1.1 Biologics
5.1.2 Biosimilar
6. EUROPEAN ERYTHROPOIETIN MARKET BY COUNTRY OUTLOOK 2022
6.1 France
6.1.1 Market Size
6.1.2 By Segment
6.1.3 By Type
6.1.4 By Application
6.2 Italy
6.2.1 Market Size
6.2.2 By Segment
6.2.3 By Type
6.2.4 By Application
6.3 Germany
6.3.1 Market Size
6.3.2 By Segment
6.3.3 By Type
6.3.4 By Application
6.4 Spain
6.4.1 Market Size
6.4.2 By Segment
6.4.3 By Type
6.4.4 By Application
6.5 UK
6.5.1 Market Size
6.5.2 By Segment
6.5.3 By Type
6.5.4 By Application
7. PATENTS AND R&D PIPELINE ANALYSIS
8. MARKET DYNAMICS
8.1 Drivers
8.1.1 Rising Focus on Developing Biosimilars in the Region
8.1.2 Use of Innovative Technologies for EPO Development
8.1.3 Rising Number of Elderly People
8.1.4 Growth in Chronic Diseases Incidences
8.1.5 Growing Pressure to Reduce Healthcare Expenditure in the Region
8.2 Challenges
8.2.1 Expensive Biologics
8.2.2 Side-Effects of EPO
8.2.3 Threat of Subsitute for CKD Anemia
9. KEY PLAYERS ANALYSIS
9.1 Amgen Inc.
9.1.1 Business Overview
9.1.2 Product Portfolio
9.1.3 Financial Overview
9.2 Johnson & Johnson
9.2.1 Business Overview
9.2.2 Product Portfolio
9.2.3 Financial Overview
9.3 Roche Group
9.3.1 Business Overview
9.3.2 Products Portfolio
9.3.3 Financial Overview
9.4 Pfizer Inc.
9.4.1 Business Overview
9.4.2 Product Portfolio
9.4.3 Financial Overview
9.5 Novartis
9.5.1 Business Overview
9.5.2 Product Portfolio
9.5.3 Financial Overvie
9.6 Teva Pharmaceuticals Ltd.
9.6.1 Business Overview
9.6.2 Products Portfolio
9.6.3 Financial Overview
9.7 Stada Arzneimittel AG
9.7.1 Business Overview
9.7.2 Products Portfolio
9.7.3 Financial Overview
9.8 Sanofi
9.8.1 Business Overview
9.8.2 Products Portfolio
9.8.3 Financial Overview
9.9 3SBio Inc.
9.9.1 Business Overview
9.9.2 Products Portfolio
9.10 Dr. Reddy's Laboratories
9.10.1 Business Overview
9.10.2 Products Portfolio
9.10.3 Financial Overview
2. RESEARCH METHODOLOGY
3. EUROPEAN PROTEIN THERAPEUTICS MARKET
3.1 Protein Therapeutics Market Vs Pharmaceutical Market
3.2 Current and Future Market Analysis for 2022
3.3 Market Segmentation
4. ERYTHROPOIETIN MARKET - INTRODUCTION
5. EUROPEAN ERYTHROPOIETIN MARKET OUTLOOK 2022
5.1 By Segment
5.1.1 Biologics
5.1.2 Biosimilar
6. EUROPEAN ERYTHROPOIETIN MARKET BY COUNTRY OUTLOOK 2022
6.1 France
6.1.1 Market Size
6.1.2 By Segment
6.1.3 By Type
6.1.4 By Application
6.2 Italy
6.2.1 Market Size
6.2.2 By Segment
6.2.3 By Type
6.2.4 By Application
6.3 Germany
6.3.1 Market Size
6.3.2 By Segment
6.3.3 By Type
6.3.4 By Application
6.4 Spain
6.4.1 Market Size
6.4.2 By Segment
6.4.3 By Type
6.4.4 By Application
6.5 UK
6.5.1 Market Size
6.5.2 By Segment
6.5.3 By Type
6.5.4 By Application
7. PATENTS AND R&D PIPELINE ANALYSIS
8. MARKET DYNAMICS
8.1 Drivers
8.1.1 Rising Focus on Developing Biosimilars in the Region
8.1.2 Use of Innovative Technologies for EPO Development
8.1.3 Rising Number of Elderly People
8.1.4 Growth in Chronic Diseases Incidences
8.1.5 Growing Pressure to Reduce Healthcare Expenditure in the Region
8.2 Challenges
8.2.1 Expensive Biologics
8.2.2 Side-Effects of EPO
8.2.3 Threat of Subsitute for CKD Anemia
9. KEY PLAYERS ANALYSIS
9.1 Amgen Inc.
9.1.1 Business Overview
9.1.2 Product Portfolio
9.1.3 Financial Overview
9.2 Johnson & Johnson
9.2.1 Business Overview
9.2.2 Product Portfolio
9.2.3 Financial Overview
9.3 Roche Group
9.3.1 Business Overview
9.3.2 Products Portfolio
9.3.3 Financial Overview
9.4 Pfizer Inc.
9.4.1 Business Overview
9.4.2 Product Portfolio
9.4.3 Financial Overview
9.5 Novartis
9.5.1 Business Overview
9.5.2 Product Portfolio
9.5.3 Financial Overvie
9.6 Teva Pharmaceuticals Ltd.
9.6.1 Business Overview
9.6.2 Products Portfolio
9.6.3 Financial Overview
9.7 Stada Arzneimittel AG
9.7.1 Business Overview
9.7.2 Products Portfolio
9.7.3 Financial Overview
9.8 Sanofi
9.8.1 Business Overview
9.8.2 Products Portfolio
9.8.3 Financial Overview
9.9 3SBio Inc.
9.9.1 Business Overview
9.9.2 Products Portfolio
9.10 Dr. Reddy's Laboratories
9.10.1 Business Overview
9.10.2 Products Portfolio
9.10.3 Financial Overview
LIST OF FIGURES:
Figure 3-1: Protein Therapeutics vs. Pharmaceutical Market of Europe (Billion US$), 2015
Figure 3-2: Protein Therapeutics Market (Billion US$) of Europe, 2015 & 2022
Figure 3-3: Protein Therapeutics Market of Europe by Segment (%), 2015
Figure 3-4: Forecast for Protein Therapeutics Market of Europe by Segment (%), 2022
Figure 5-1: Erythropoietin Market of Europe (Billion US$), 2015 & 2022
Figure 5-2: Biologic Erythropoietin Market of Europe (Million US$), 2015 & 2022
Figure 5-3: Biosimilar Erythropoietin Market of Europe (Million US$), 2015 & 2022
Figure 6-1: Share of Countries in European Erythropoietin Market (%), 2015
Figure 6-2: Forecast for Share of Countries in European Erythropoietin Market (%), 2022
Figure 6-3: Erythropoietin Market of France (Million US$), 2015 & 2022
Figure 6-4: Biologic Erythropoietin Market of France (Million US$), 2015 & 2022
Figure 6-5: Biosimilar Erythropoietin Market of France (Million US$), 2015 & 2022
Figure 6-6: Prevalence of CKD in France (Million), 2015 & 2022
Figure 6-7: Incidences of Cancer in France ('000), 2015 & 2025
Figure 6-8: Erythropoietin Market of Italy (Million US$), 2015 & 2022
Figure 6-9: Biologic Erythropoietin Market of Italy (Million US$), 2015 & 2022
Figure 6-10: Biosimilar Erythropoietin Market of Italy (Million US$), 2015 & 2022
Figure 6-11: Prevalence of CKD in Italy (Million), 2015 & 2022
Figure 6-12: Incidences of Cancer in Italy ('000), 2015 & 2025
Figure 6-13: Erythropoietin Market of Germany (Million US$), 2015 & 2022
Figure 6-14: Biologic Erythropoietin Market of Germany (Million US$), 2015 & 2022
Figure 6-15: Biosimilar Erythropoietin Market of Germany (Million US$), 2015 & 2022
Figure 6-16: Prevalence of CKD in Germany (Million), 2015 & 2022
Figure 6-17: Incidences of Cancer in Germany ('000), 2015 & 2025
Figure 6-18: Erythropoietin Market of Spain (Million US$), 2015 & 2022
Figure 6-19: Biologic Erythropoietin Market of Spain (Million US$), 2015 & 2022
Figure 6-20: Biosimilar Erythropoietin Market of Spain (Million US$), 2015 & 2022
Figure 6-21: Prevalence of CKD in Spain (Million), 2015 & 2022
Figure 6-22: Incidences of Cancer in Spain ('000), 2015 & 2025
Figure 6-23: Erythropoietin Market of UK (Million US$), 2015 & 2022
Figure 6-24: Biologic Erythropoietin Market of UK (Million US$), 2015 & 2022
Figure 6-25: Biosimilar Erythropoietin Market of UK (Million US$), 2015 & 2022
Figure 6-26: Prevalence of CKD in UK (Million), 2015 & 2022
Figure 6-27: Incidences of Cancer in UK ('000), 2015 & 2025
Figure 8-1: Population above 60 Years in Europe (Billion), 2015 & 2050
Figure 8-2: Incidences of Cancer in Europe (Million), 2015 & 2025
Figure 9-1: Amgen Inc. - Product Sales by Geography (%), 2015
Figure 9-2: Johnson & Johnson - Sales by Business Segment (%), 2015
Figure 9-3: Johnson & Johnson - Sales by Geography (%), 2015
Figure 9-4: Roche - Sales by Business Segment (%), 2015
Figure 9-5: Roche - Sales by Geography (%), 2015
Figure 9-6: Pfizer Inc. - Revenue by Business Segment (%), 2015
Figure 9-7: Pfizer Inc. - Revenue by Geography (%), 2015
Figure 9-8: Novartis - Sales by Business Segment (%), 2015
Figure 9-9: Novartis - Sales by Geography (%), 2015
Figure 9-10: Teva Pharmaceuticals Ltd. - Revenue by Business Segment (%), 2015
Figure 9-11: Teva Pharmaceuticals Ltd. - Revenue by Geography (%), 2015
Figure 9-12: Stada - Sales by Business Segment (%), 2015
Figure 9-13: Stada - Sales by Geography (%), 2015
Figure 9-14: Sanofi - Sales by Business Segment (%), 2015
Figure 9-15: Sanofi - Sales by Geography (%), 2015
Figure 9-16: Dr. Reddy's Laboratories - Revenue by Business Segment (%), 2015
Figure 9-17: Dr. Reddy's Laboratories - Revenue by Geography (%), 2015
Figure 3-1: Protein Therapeutics vs. Pharmaceutical Market of Europe (Billion US$), 2015
Figure 3-2: Protein Therapeutics Market (Billion US$) of Europe, 2015 & 2022
Figure 3-3: Protein Therapeutics Market of Europe by Segment (%), 2015
Figure 3-4: Forecast for Protein Therapeutics Market of Europe by Segment (%), 2022
Figure 5-1: Erythropoietin Market of Europe (Billion US$), 2015 & 2022
Figure 5-2: Biologic Erythropoietin Market of Europe (Million US$), 2015 & 2022
Figure 5-3: Biosimilar Erythropoietin Market of Europe (Million US$), 2015 & 2022
Figure 6-1: Share of Countries in European Erythropoietin Market (%), 2015
Figure 6-2: Forecast for Share of Countries in European Erythropoietin Market (%), 2022
Figure 6-3: Erythropoietin Market of France (Million US$), 2015 & 2022
Figure 6-4: Biologic Erythropoietin Market of France (Million US$), 2015 & 2022
Figure 6-5: Biosimilar Erythropoietin Market of France (Million US$), 2015 & 2022
Figure 6-6: Prevalence of CKD in France (Million), 2015 & 2022
Figure 6-7: Incidences of Cancer in France ('000), 2015 & 2025
Figure 6-8: Erythropoietin Market of Italy (Million US$), 2015 & 2022
Figure 6-9: Biologic Erythropoietin Market of Italy (Million US$), 2015 & 2022
Figure 6-10: Biosimilar Erythropoietin Market of Italy (Million US$), 2015 & 2022
Figure 6-11: Prevalence of CKD in Italy (Million), 2015 & 2022
Figure 6-12: Incidences of Cancer in Italy ('000), 2015 & 2025
Figure 6-13: Erythropoietin Market of Germany (Million US$), 2015 & 2022
Figure 6-14: Biologic Erythropoietin Market of Germany (Million US$), 2015 & 2022
Figure 6-15: Biosimilar Erythropoietin Market of Germany (Million US$), 2015 & 2022
Figure 6-16: Prevalence of CKD in Germany (Million), 2015 & 2022
Figure 6-17: Incidences of Cancer in Germany ('000), 2015 & 2025
Figure 6-18: Erythropoietin Market of Spain (Million US$), 2015 & 2022
Figure 6-19: Biologic Erythropoietin Market of Spain (Million US$), 2015 & 2022
Figure 6-20: Biosimilar Erythropoietin Market of Spain (Million US$), 2015 & 2022
Figure 6-21: Prevalence of CKD in Spain (Million), 2015 & 2022
Figure 6-22: Incidences of Cancer in Spain ('000), 2015 & 2025
Figure 6-23: Erythropoietin Market of UK (Million US$), 2015 & 2022
Figure 6-24: Biologic Erythropoietin Market of UK (Million US$), 2015 & 2022
Figure 6-25: Biosimilar Erythropoietin Market of UK (Million US$), 2015 & 2022
Figure 6-26: Prevalence of CKD in UK (Million), 2015 & 2022
Figure 6-27: Incidences of Cancer in UK ('000), 2015 & 2025
Figure 8-1: Population above 60 Years in Europe (Billion), 2015 & 2050
Figure 8-2: Incidences of Cancer in Europe (Million), 2015 & 2025
Figure 9-1: Amgen Inc. - Product Sales by Geography (%), 2015
Figure 9-2: Johnson & Johnson - Sales by Business Segment (%), 2015
Figure 9-3: Johnson & Johnson - Sales by Geography (%), 2015
Figure 9-4: Roche - Sales by Business Segment (%), 2015
Figure 9-5: Roche - Sales by Geography (%), 2015
Figure 9-6: Pfizer Inc. - Revenue by Business Segment (%), 2015
Figure 9-7: Pfizer Inc. - Revenue by Geography (%), 2015
Figure 9-8: Novartis - Sales by Business Segment (%), 2015
Figure 9-9: Novartis - Sales by Geography (%), 2015
Figure 9-10: Teva Pharmaceuticals Ltd. - Revenue by Business Segment (%), 2015
Figure 9-11: Teva Pharmaceuticals Ltd. - Revenue by Geography (%), 2015
Figure 9-12: Stada - Sales by Business Segment (%), 2015
Figure 9-13: Stada - Sales by Geography (%), 2015
Figure 9-14: Sanofi - Sales by Business Segment (%), 2015
Figure 9-15: Sanofi - Sales by Geography (%), 2015
Figure 9-16: Dr. Reddy's Laboratories - Revenue by Business Segment (%), 2015
Figure 9-17: Dr. Reddy's Laboratories - Revenue by Geography (%), 2015
LIST OF TABLES:
Table 6-1: Erythropoietin Market of France by Type (Million US$), 2015 & 2022
Table 6-2: Erythropoietin Market of Italy by Type (Million US$), 2015 & 2022
Table 6-3: Erythropoietin Market of Germany by Type (Million US$), 2015 & 2022
Table 6-4: Erythropoietin Market of Spain by Type (Million US$), 2015 & 2022
Table 6-5: Erythropoietin Market of UK by Type (Million US$), 2015 & 2022
Table 7-1: Erythropoietin Patent Analysis of Europe
Table 7-2: Erythropoietin Product Pipeline
Table 9-1: Amgen Inc. - Commercialized EPO Products
Table 9-2: Amgen Inc. - Financials (Billion US$), 2013, 2014 & 2015
Table 9-3: Amgen Inc. - EPO Product Sales (Billion US$), 2013, 2014 & 2015
Table 9-4: Johnson & Johnson - Commercialized EPO Products
Table 9-5: Johnson & Johnson - Financials (Billion US$), 2013, 2014 & 2015
Table 9-6: Johnson & Johnson - EPO Product Sales (Billion US$), 2013, 2014 & 2015
Table 9-7: Roche - Commercialized EPO Products
Table 9-8: Roche - Financials (Billion US$), 2013, 2014 & 2015
Table 9-9: Roche - Europe EPO Product Sales (Billion US$), 2013, 2014 & 2015
Table 9-10: Pfizer Inc. - Commercialized EPO Products
Table 9-11: Pfizer Inc. - Financials (Billion US$), 2013, 2014 & 2015
Table 9-12: Novartis - Commercialized EPO Products
Table 9-13: Novartis - Financials (Billion US$), 2013, 2014 & 2015
Table 9-14: Teva Pharmaceuticals Ltd. - Commercialized EPO Products
Table 9-15: Teva Pharmaceuticals Ltd. - Financials (Billion US$), 2013, 2014 & 2015
Table 9-16: Stada - Commercialized EPO Products
Table 9-17: Stada - Financials (Billion US$), 2013, 2014 & 2015
Table 9-18: Sanofi - Commercialized EPO Products
Table 9-19: Sanofi - Financials (Billion US$), 2013, 2014 & 2015
Table 9-20: 3SBio Inc. - Commercialized EPO Products
Table 9-21: Dr. Reddy's Laboratories - Commercialized EPO Products
Table 9-22: Dr. Reddy's Laboratories - Financials (Billion US$), 2013, 2014, & 2015
Table 6-1: Erythropoietin Market of France by Type (Million US$), 2015 & 2022
Table 6-2: Erythropoietin Market of Italy by Type (Million US$), 2015 & 2022
Table 6-3: Erythropoietin Market of Germany by Type (Million US$), 2015 & 2022
Table 6-4: Erythropoietin Market of Spain by Type (Million US$), 2015 & 2022
Table 6-5: Erythropoietin Market of UK by Type (Million US$), 2015 & 2022
Table 7-1: Erythropoietin Patent Analysis of Europe
Table 7-2: Erythropoietin Product Pipeline
Table 9-1: Amgen Inc. - Commercialized EPO Products
Table 9-2: Amgen Inc. - Financials (Billion US$), 2013, 2014 & 2015
Table 9-3: Amgen Inc. - EPO Product Sales (Billion US$), 2013, 2014 & 2015
Table 9-4: Johnson & Johnson - Commercialized EPO Products
Table 9-5: Johnson & Johnson - Financials (Billion US$), 2013, 2014 & 2015
Table 9-6: Johnson & Johnson - EPO Product Sales (Billion US$), 2013, 2014 & 2015
Table 9-7: Roche - Commercialized EPO Products
Table 9-8: Roche - Financials (Billion US$), 2013, 2014 & 2015
Table 9-9: Roche - Europe EPO Product Sales (Billion US$), 2013, 2014 & 2015
Table 9-10: Pfizer Inc. - Commercialized EPO Products
Table 9-11: Pfizer Inc. - Financials (Billion US$), 2013, 2014 & 2015
Table 9-12: Novartis - Commercialized EPO Products
Table 9-13: Novartis - Financials (Billion US$), 2013, 2014 & 2015
Table 9-14: Teva Pharmaceuticals Ltd. - Commercialized EPO Products
Table 9-15: Teva Pharmaceuticals Ltd. - Financials (Billion US$), 2013, 2014 & 2015
Table 9-16: Stada - Commercialized EPO Products
Table 9-17: Stada - Financials (Billion US$), 2013, 2014 & 2015
Table 9-18: Sanofi - Commercialized EPO Products
Table 9-19: Sanofi - Financials (Billion US$), 2013, 2014 & 2015
Table 9-20: 3SBio Inc. - Commercialized EPO Products
Table 9-21: Dr. Reddy's Laboratories - Commercialized EPO Products
Table 9-22: Dr. Reddy's Laboratories - Financials (Billion US$), 2013, 2014, & 2015
